Enzymatic stability and immunoregulatory efficacy of a synthetic indolicidin analogue with regular enantiomeric sequence

ACS Medicinal Chemistry Letters

Volumn 4, Issue 6, 2013, Pages 522-526

  Chang, Ching Yun ^a   Lin, Chih Wei ^a   Chiang, Sheng Kuo ^a   Chen, Po Ling ^a   Huang, Chiung Yi ^a   Liu, Shih Jen ^a,b   Chong, Pele ^a,b   Huang, Ming Hsi ^a,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Host defense peptides; Immunoregulation; Peptidomimetic stereoisomer; Vaccine adjuvants

Indexed keywords

INDOLICIDIN; LD INDOLICIDIN; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG TOLERANCE; ENANTIOMER; ENZYMATIC DEGRADATION; ENZYME STABILITY; IMMUNOREGULATION; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; SOLID PHASE SYNTHESIS;

BOVINAE; MUS;

EID: 84879079732     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400081f     Document Type: Article

References (19)

1. Huang, M. H.; Leng, C. H.; Liu, S. J.; Chen, H. W.; Sia, C.; Chong, P. Vaccine Delivery Systems Based on Amphiphilic Bioresorbable Polymers and Their Role in Vaccine Immunogenicity. In Immunogenicity; Villanueva, C. J., Ed.; Nova Science Publishers: New York, 2011; pp 61-90.
2. Schubert, C. Boosting our best shot. Nat. Med. 2009, 15, 984-988.
3. O'Hagan, D.; De Gregorio, E. The path to a successful vaccine adjuvant: 'The long and winding road'. Drug Discovery Today 2009, 14, 541-551.
4. Hubbell, J. A.; Thomas, S. N.; Swartz, M. A. Materials engineering for immunomodulation. Nature 2009, 462, 449-460.
5. Seder, R. A.; Hill, A. V. S. Vaccines against intracellular infections requiring cellular immunity. Nature 2000, 406, 793-798.
6. Rudra, J. S.; Tian, Y. F.; Jung, J. P.; Collier, J. H. A self-assembling peptide acting as an immune adjuvant. Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 622-627.
7. Iwasaki, A.; Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327, 291-295.
8. Kruse, T.; Kristensen, H. H. Using antimicrobial host defense peptides as anti-infective and immunomodulatory agents. Expert Rev. Anti-Infect. Ther. 2008, 6, 887-895.
9. Kovacs-Nolan, J.; Latimer, L.; Landi, A.; Jenssen, H.; Hancock, R. E. W.; Babiuk, L. A.; van Drunen Littel-van den Hurk, S. The novel adjuvant combination of CpG ODN indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. Vaccine 2009, 27, 2055-2064.
10. Falla, T.; Hancock, R. E. W. Improved activity of a synthetic indolicidin analog. Antimicrob. Agents Chemother. 1997, 41, 771-775.
11. Osapay, K.; Tran, D.; Ladokhin, A. S.; White, S. H.; Henschen, A. H.; Selsted, M. E. Formation and characterization of a single Trp-Trp crosslink in indolicidin that confers protease stability without altering antimicrobial activity. J. Biol. Chem. 2000, 275, 12017-12022.
12. Shepherd, N. E.; Abbenante, G.; Fairlie, D. P. Consecutive cyclic pentapeptide modules form short α-helices that are very stable to water and denaturants. Angew. Chem., Int. Ed. 2004, 43, 2687-2690.
13. Rosenthal-Aizman, K.; Svensson, G.; Unden, A. Self-assembling peptide nanotubes from enantiomeric pairs of cyclic peptides with alternating D and L amino acid residues. J. Am. Chem. Soc. 2004, 126, 3372-3373.
14. McElhaney, J. E.; Xie, D.; Hager, W. D.; Barry, M. B.; Wang, Y.; Kleppinger, A.; Ewen, C.; Kane, K. P.; Bleackley, R. C. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 2006, 176, 6333-6339.
15. Webster, R. G.; Govorkova, E. A. H5N1 Influenza: continuing evolution and spread. N. Engl. J. Med. 2006, 355, 2174-2177.
16. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. Wkly. Epidemiol. Rec. 2012, 87, 83-96.
17. Wilkinson, T. M.; Li, C. K. F.; Chui, C. S. C.; Huang, A. K. Y.; Perkins, M.; Liebner, J. C.; Lambkin-Williams, R.; Gilbert, A.; Oxford, J.; Nicholas, B.; Staples, K. J.; Dong, T.; Douek, D. C.; McMichael, A. J.; Xu, X. N. Pre-existing influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 2012, 18, 274-281.
18. Mosca, F.; Tritto, E.; Muzzi, A.; Monaci, E.; Bagnoli, F.; Iavarone, C.; O'Hagan, D.; Rappuoli, R.; de Gregorio, E. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 10501-10506.
19. Offit, P. A.; Jew, R. K. Addressing parents' concerns: do vaccines contain harmful preservatives adjuvants, additives, or residuals? Pediatrics 2003, 112, 1394-1397.